Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia

被引：11
作者：
Alladi, Charanraj Goud [1 ,2 ,3 ]
RajKumar, Ravi Philip [4 ]
Adithan, Surendiran [1 ]
Marie-Claire, Cynthia [2 ,3 ]
Bellivier, Frank [2 ,3 ,5 ,6 ]
Shewade, Deepak Gopal [1 ]
机构：
[1] Jawaharlal Inst Postgrad Med Educ & Res, Dept Pharmacol, Pondicherry 605006, India
[2] INSERM, U1144, F-75006 Paris, France
[3] Univ Sorbonne Paris Cite, UMR S 1144, F-75006 Paris, France
[4] Jawaharlal Inst Postgrad Med Educ & Res, Dept Psychiat, Pondicherry 605006, India
[5] GH St Louis Lariboisiere F Widal, AP HP, Pole Psychiat & Med Addictol, F-75475 Paris 10, France
[6] Fdn FondaMental, F-94000 Creteil, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2019年 / 33卷 / 03期
关键词：
dopamine; genetic polymorphism; risperidone; schizophrenia; serotonin; ANTIPSYCHOTIC-DRUG TREATMENT; 5-HT2A RECEPTOR; CLINICAL-RESPONSE; THERAPEUTIC RESPONSE; CLOZAPINE RESPONSE; NEGATIVE SYMPTOMS; PROMOTER REGION; 1ST-EPISODE SCHIZOPHRENIA; ALLELIC VARIATION; ASSOCIATION;
D O I：
10.1111/fcp.12424
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Treatment response to antipsychotic drugs is variable and conflicting results have been obtained while studying the influence of DRD2 and HTR2 genetic variants on antipsychotic drug efficacy. To explore further, the present study aimed to assess the influence of DRD2 -141 C Ins/Del, Taq1A and HTR2A -1438 G/A, 102T/C and HTR2C -759 C/T genetic polymorphisms in response to risperidone in patients with schizophrenia. The study was conducted among the n = 320 South Indian patients with schizophrenia who received risperidone treatment (4-8 mg per day) for a minimum of four weeks. Genotyping was done by real-time PCR. Antipsychotic response was assessed using CGI-I score in cross-sectional group, PANSS score in prospective group at baseline and after receiving the risperidone therapy. DRD2 -141 C Ins/Del (n = 310, Ins/Ins = 177, Ins/Del+ Del/Del = 133, OR 0.70, 95% CI 0.4-1.2 p 0.2), Taq1A (n = 320, AA = 35, AG = 132, GG = 153, p 0.2), HTR2A -1438 G/A (n = 320, AA = 39, AG = 164, GG = 117, p 0.2), HTR2A 102T/C (n = 320, CC = 115, CT = 165, TT = 40, p 0.1) HTR2C -759 C/T (females n = 132, CC = 65, CT+TT = 67, OR 1.3, 95% CI 0.6-2.8, p 0.5; males n = 186, C = 120, T = 66, OR 1.2, 95% CI 0.6-2.4, p 0.4) genetic polymorphisms did not show any association with antipsychotic response to risperidone. DRD2 -141 C Ins/Del, Taq1A, HTR2A -1438 G/A, 102T/C and HTR2C -759 C/T genetic variants are not associated with antipsychotic response to risperidone.
引用
收藏
页码：355 / 364
页数：10
相关论文
共 61 条
[11]   Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients [J].
Dahmen, N ;
Müller, MJ ;
Germeyer, S ;
Rujescu, D ;
Anghelescu, I ;
Hiemke, C ;
Wetzel, H .
SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) :223-225
[12]  
Ellingrod Vicki L, 2003, Psychopharmacol Bull, V37, P109
[13]   5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia [J].
Ellingrod, VL ;
Perry, PJ ;
Lund, BC ;
Bever-Stille, K ;
Pleming, F ;
Holman, TL ;
Miller, D .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) :622-624
[14]   A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia [J].
Haas, Magali ;
Unis, Alan S. ;
Armenteros, Jorge ;
Copenhaver, Margaret D. ;
Quiroz, Jorge A. ;
Kushner, Stuart F. .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (06) :611-621
[15]   Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics [J].
Hamdani, N ;
Bonnière, M ;
Adès, J ;
Hamon, M ;
Boni, C ;
Gorwood, P .
NEUROSCIENCE LETTERS, 2005, 377 (01) :69-74
[16]   Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response [J].
Huang, Eric ;
Maciukiewicz, Malgorzata ;
Zai, Clement C. ;
Tiwari, Arun K. ;
Li, Jiang ;
Potkin, Steven G. ;
Lieberman, Jeffrey A. ;
Meltzer, Herbert Y. ;
Mueller, Daniel J. ;
Kennedy, James L. .
PHARMACOGENOMICS, 2016, 17 (02) :103-109
[17]   Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations [J].
Hwang, R ;
Shinkai, T ;
De Luca, V ;
Müller, DJ ;
Ni, XQ ;
Macciardi, F ;
Potkin, S ;
Lieberman, JA ;
Meltzer, HY ;
Kennedy, JL .
PSYCHOPHARMACOLOGY, 2005, 181 (01) :179-187
[18]   Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia [J].
Ikeda, Masashi ;
Yamanouchi, Yoshio ;
Kinoshita, Yoko ;
Kitajima, Tsuyoshi ;
Yoshimura, Reiji ;
Hashimoto, Shuji ;
O'Donovan, Michael C. ;
Nakamura, Jun ;
Ozaki, Norio ;
Iwata, Nakao .
PHARMACOGENOMICS, 2008, 9 (10) :1437-1443
[19]  
Jonsson E, 1996, LANCET, V347, P1831
[20]  
Joober R, 1999, J PSYCHIATR NEUROSCI, V24, P141
1234567